Clinical Utility of Extracellular RNA for Biomarker Development (UH2/UH3)

Post Date

August 3rd 2012

Application Due Date

November 13th 2012

Funding Opportunity Number

RFA-RM-12-013

CFDA Number(s)

93.310

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $4000000

• Award Range:

  $None - $None

Grant Description

The NIH invites applications for projects that will identify and qualify extracellular RNA (exRNA)-based biomarkers derived from human body fluids, such as blood, saliva, urine, breast milk, amniotic fluid, cerebrospinal fluid, ascites and pleural effusions, in order to diagnose and monitor disease progression and response to therapy. The overall goal of this project is to develop reliable, well-defined and clinically relevant biomarkers derived from extracellular RNA that measure tangible benefits for patients in terms of how they feel, function, and survive in clinical trials. Appropriate studies under this FOA will identify and validate candidate exRNA-based biomarkers in well-defined patient populations, provide new technologies to monitor biomarkers or establish reliable assays for validated markers

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-013.html